Brokers Offer Predictions for Immunovant FY2025 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Immunovant in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($1.88) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Cantor Fitzgerald also issued estimates for Immunovant’s FY2026 earnings at ($2.92) EPS.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08).

Several other research firms also recently issued reports on IMVT. Bank of America dropped their price target on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, January 15th. Wells Fargo & Company lowered their price target on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Guggenheim decreased their price target on Immunovant from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Wolfe Research cut shares of Immunovant from an “outperform” rating to a “peer perform” rating in a research report on Friday, January 3rd. Finally, Jefferies Financial Group started coverage on Immunovant in a report on Monday. They set a “hold” rating and a $20.00 target price for the company. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.55.

Immunovant Stock Performance

NASDAQ IMVT opened at $19.42 on Thursday. The firm’s fifty day moving average price is $22.06 and its two-hundred day moving average price is $26.68. Immunovant has a fifty-two week low of $17.65 and a fifty-two week high of $35.97. The stock has a market cap of $3.30 billion, a PE ratio of -7.41 and a beta of 0.68.

Hedge Funds Weigh In On Immunovant

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in Immunovant in the 4th quarter valued at about $76,000. Two Seas Capital LP boosted its position in shares of Immunovant by 123.4% during the 4th quarter. Two Seas Capital LP now owns 1,511,614 shares of the company’s stock valued at $37,443,000 after acquiring an additional 835,000 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Immunovant in the fourth quarter valued at about $1,115,000. Twinbeech Capital LP purchased a new stake in Immunovant in the fourth quarter valued at $314,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Immunovant in the 4th quarter valued at approximately $270,000. 47.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Immunovant news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the stock in a transaction on Monday, January 13th. The shares were bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CTO Jay S. Stout sold 2,195 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $23.59, for a total value of $51,780.05. Following the transaction, the chief technology officer now directly owns 139,991 shares of the company’s stock, valued at approximately $3,302,387.69. The trade was a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,510 shares of company stock worth $656,886 in the last three months. 5.90% of the stock is owned by insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.